Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intelgenx Technologies Corp T.IGX

Alternate Symbol(s):  IGXT

Healthcare
IntelGenx Technologies Corp. is a Canada-based drug delivery company. The Company provides single-site, end-to-end contract development and manufacturing services of oral thin film and transdermal drug products for the pharmaceutical and animal health markets, spanning the entire drug development and commercial product cycle. The Company’s film technologies, including VersaFilm, DisinteQ... see more

Recent & Breaking News (TSX:IGX)

CORRECTION - IntelGenx to Participate in the 35th Annual Roth Conference

GlobeNewswire March 9, 2023

IntelGenx to Participate in the 35th Annual Roth Conference

GlobeNewswire March 9, 2023

IntelGenx Receives USPTO Notice of Allowance for Loxapine Orange Book Eligible Patent

GlobeNewswire February 21, 2023

IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm® for the Treatment of Parkinson's Disease

GlobeNewswire February 9, 2023

IntelGenx and Arwan Enter into a Supply Agreement for RIZAPORT® in MENA Countries

GlobeNewswire January 23, 2023

IntelGenx Receives Fourth and Final Loan Tranche from atai

GlobeNewswire January 9, 2023

IntelGenx Corp. (TSX:IGX) collaborating with UPEI to evaluate VetaFilm in dogs & cats

Jonathon Brown December 7, 2022

IntelGenx Announces Collaboration with UPEI to Evaluate Acceptance and Preference of VetaFilm(TM) Platform in Dogs and Cats

GlobeNewswire December 7, 2022

IntelGenx Receives FDA PDUFA Date for RIZAFILM®

GlobeNewswire November 22, 2022

IntelGenx Reschedules Third Quarter 2022 Conference Call Due to Technical Issues Experienced Today by Webcast Vendor

GlobeNewswire November 10, 2022

IntelGenx Reports Third Quarter 2022 Financial Results

GlobeNewswire November 10, 2022

IntelGenx Enters into Feasibility & Development Agreement For CBD-Infused VetaFilm(TM)

GlobeNewswire November 9, 2022

IntelGenx to Report Third Quarter 2022 Financial Results on November 10, 2022 - Conference Call to Follow

GlobeNewswire November 3, 2022

IntelGenx Files Provisional U.S. Patent Application for Advanced Oral Film Formulation Improving Cannabinoid Onset of Action

GlobeNewswire November 2, 2022

IntelGenx Receives FDA GDUFA Date for Xiromed-Partnered Development Candidate, Buprenorphine Buccal Film

GlobeNewswire October 25, 2022

IntelGenx Corp. (TSX:IGX) announces issuance of New U.S. patent covering VersaFilm technology

Azuka Onwuka October 20, 2022

IntelGenx Announces Issuance of New U.S. Patent Covering VersaFilm® Technology

GlobeNewswire October 20, 2022

IntelGenx Submits Response to CRL from FDA for RIZAPORT® VersaFilm®

GlobeNewswire October 18, 2022

IntelGenx's Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug Candidate

GlobeNewswire October 13, 2022

IntelGenx Announces Enrollment Reaches Halfway Mark in 'BUENA' Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer's Disease

GlobeNewswire September 8, 2022